Professional Advisory Services Inc. Lowers Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Professional Advisory Services Inc. has reduced its stake in Thermo Fisher Scientific by 32.1%, selling 17,056 shares, leaving them with 36,142 shares valued at approximately $14.65 million.
• Several institutional investors have entered or increased their positions in Thermo Fisher Scientific, with 89.23% of the stock owned by institutional investors and hedge funds.
• Thermo Fisher Scientific recently declared a quarterly dividend of $0.43, representing a 0.4% yield, with an ex-dividend date on September 15th.

Professional Advisory Services Inc. lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 32.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 36,142 shares of the medical research company's stock after selling 17,056 shares during the period. Thermo Fisher Scientific accounts for approximately 2.0% of Professional Advisory Services Inc.'s investment portfolio, making the stock its 29th biggest position. Professional Advisory Services Inc.'s holdings in Thermo Fisher Scientific were worth $14,654,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Bernard Wealth Management Corp. purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $25,000. CBIZ Investment Advisory Services LLC grew its stake in Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after acquiring an additional 33 shares in the last quarter. Ameriflex Group Inc. purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $30,000. Anderson Financial Strategies LLC purchased a new stake in Thermo Fisher Scientific during the 1st quarter valued at about $30,000. Finally, Keystone Global Partners LLC purchased a new stake in Thermo Fisher Scientific during the 1st quarter valued at about $31,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Activity at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at $1,142,408.97. This trade represents a 14.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock valued at $14,182,963 in the last ninety days. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Down 0.6%

Shares of TMO traded down $3.04 during midday trading on Tuesday, reaching $471.95. The stock had a trading volume of 2,126,564 shares, compared to its average volume of 2,392,631. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $623.77. The company's fifty day simple moving average is $472.99 and its two-hundred day simple moving average is $448.55. The company has a market cap of $178.21 billion, a price-to-earnings ratio of 27.33, a PEG ratio of 2.56 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period last year, the business earned $5.37 EPS. The company's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Wall Street Analysts Forecast Growth

TMO has been the subject of several analyst reports. HSBC reissued a "hold" rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Wells Fargo & Company dropped their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research note on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the company an "outperform" rating in a research note on Tuesday, September 2nd. Raymond James Financial reissued an "outperform" rating and issued a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, Evercore ISI dropped their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Sixteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $588.35.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.